Cargando…

The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece

INTRODUCTION: The current treatment goal in Major Depressive Disorder (MDD) is functional recovery (Zimmerman M et al, 2012). However, finding the “right dose for the right patient” may be challenging and the dose-response relationship for antidepressant efficacy remains controversial (Hieronymus F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papalexi, E., Kakkavas, P., Vassos, D., Mylonaki, T., Partsafyllidis, D., Mageiria, S., Nestoris, C., Galanopoulos, A., Ettrup, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471327/ http://dx.doi.org/10.1192/j.eurpsy.2021.905

Ejemplares similares

Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
por: Galanopoulos, A., et al.
Publicado: (2021)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
por: Papalexi, Eugenia, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
por: Mahableshwarkar, Atul R., et al.
Publicado: (2015)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
por: Montano, C Brendan, et al.
Publicado: (2022)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

Findings from real-world clinical practice on tDCS treatment of MDD
por: Panhelainen, A.
Publicado: (2023)

Study design of VGOAL-J: an observational, prospective cohort study to assess effectiveness of vortioxetine on goal achievement and work productivity in patients with MDD in Japan
por: Watanabe, K., et al.
Publicado: (2022)

Effectiveness of vortioxetine in real-world clinical practice: Interim results from the relieve study
por: Mattingly, G., et al.
Publicado: (2021)

Effectiveness of vortioxetine in real-world clinical practice: Italian cohort results from the global RELIEVE study
por: De Filippis, S., et al.
Publicado: (2022)

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
por: Mattingly, Gregory W., et al.
Publicado: (2022)

PS83. Impact of Vortioxetine on Functional Capacity in MDD Patients with Subjective Cognitive Dysfunction: A Post-hoc Analysis of the University of California San Diego Performance-Based Skills Assessment
por: Jacobson, William, et al.
Publicado: (2016)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Effectiveness of vortioxetine in real-world clinical practice: French cohort results from the global RELIEVE study
por: Polosan, M., et al.
Publicado: (2022)

Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study
por: Levada, Oleg A., et al.
Publicado: (2020)

Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
por: Chokka, Pratap, et al.
Publicado: (2021)

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
por: Yuan, Hsinsung, et al.
Publicado: (2019)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study
por: Vieta, Eduard, et al.
Publicado: (2019)

Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study
por: Wee, Soon Nan, et al.
Publicado: (2023)

Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis
por: Li, Zejun, et al.
Publicado: (2023)

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)
por: Chokka, Pratap, et al.
Publicado: (2019)

Why is Diagnosing MDD Challenging?
Publicado: (2016)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
por: Balasubramanian, Vijay P., et al.
Publicado: (2022)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study
por: De Filippis, Sergio, et al.
Publicado: (2022)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
por: Rancans, Elmars, et al.
Publicado: (2020)

POSTPARTUM GAD IS A RISK FACTOR FOR POSTPARTUM MDD: THE COURSE AND LONGITUDINAL RELATIONSHIPS OF POSTPARTUM GAD AND MDD
por: Prenoveau, Jason, et al.
Publicado: (2013)

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
por: Moon, Seok Woo, et al.
Publicado: (2023)

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
por: Mattingly, Gregory, et al.
Publicado: (2023)

Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder
por: Yasui-Furukori, Norio, et al.
Publicado: (2020)

From MDD concepts to experiments and illustrations
por: Babau, Jean-Philippe, et al.
Publicado: (2006)

The neurocognitive profile of post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), and PTSD with comorbid MDD
por: Koopowitz, Sheri‐Michelle, et al.
Publicado: (2021)

Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study
por: Polosan, Mircea, et al.
Publicado: (2022)

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
por: Wang, Gang, et al.
Publicado: (2022)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2017)

The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
por: Fu, Jie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6aq93gqp1n4dodq1ffm5l6gnsg